I think it's an important part of the agreement, an agreement to have a dialogue about biotechnology issues, and low-level presence is certainly one of them. With more biotechnology products being grown around the world and more acreage and more different types of products, it's really important we have approvals for these products in all our markets, because all these markets have zero tolerance. If you have even one seed that's not authorized in a market, it can cause a disruption. It can cause the turning away of a vessel. These vessels are worth $25 million or $30 million, so that can be a serious economic problem.
Low-level presence policies are important. This agreement allows us to have a consultation with the Europeans about what that means and how important it is to sustaining trade from their point of view, in terms of security of supply from products coming in from Canada, and from our point of view, predictability for exports. I think that's an important part of the agreement.